SRR26320064
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- INTERFERON_ALPHA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.430
- IL2_STAT5_SIGNALING+0.360
- TGF_BETA_SIGNALING+0.350
- APOPTOSIS+0.300
- UV_RESPONSE_DN+0.280
- PI3K_AKT_MTOR_SIGNALING+0.270
- PROTEIN_SECRETION+0.250
Top 10 suppressed
- E2F_TARGETS-0.350
- G2M_CHECKPOINT-0.320
- KRAS_SIGNALING_DN-0.270
- CHOLESTEROL_HOMEOSTASIS-0.240
- SPERMATOGENESIS-0.240
- PANCREAS_BETA_CELLS-0.170
- BILE_ACID_METABOLISM-0.140
- FATTY_ACID_METABOLISM-0.140
- GLYCOLYSIS-0.130
- OXIDATIVE_PHOSPHORYLATION-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_775HDFNY | pilocytic astrocytoma | — | 0.833 |
| 2 | SRR12696729 | — | — | 0.828 |
| 3 | BS_7C40TRCY | Med | Medulloblastoma | 0.828 |
| 4 | BS_49VCQD19 | Neurofibroma | — | 0.826 |
| 5 | SJEPD030512_D1.RNA-Seq | EPN | Supratentorial EPN | 0.824 |
| 6 | BS_Z9ZS6ZS2 | MPNST | — | 0.824 |
| 7 | MNG464 | — | — | 0.816 |
| 8 | BS_9P9MB8X8 | low-grade glioma | — | 0.815 |
| 9 | SRR934745 | — | — | 0.815 |
| 10 | BS_9HA238XS | Neurofibroma | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |